Known targets — ChEMBL curated mechanism
CDK1CDK10CDK11BCDK12CDK13CDK14CDK15CDK16CDK17CDK18CDK19CDK2CDK20CDK3CDK4CDK5CDK6CDK7CDK8CDK9
The experimentally established mechanism targets of At-7519. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 known ✓ | O94921 | 11/20 | 0.90 |
| ▸ | CDK2 known ✓ | P24941 | 9/20 | 0.90 |
| ▸ | CDK1 known ✓ | P06493 | 4/20 | 0.90 |
| ▸ | CDK5 known ✓ | Q00535 | 3/20 | 0.90 |
| ▸ | CDK4 known ✓ | P11802 | 2/20 | 0.90 |
| ▸ | CDK9 known ✓ | P50750 | 2/20 | 0.90 |
| ▸ | CDK11B known ✓ | P21127 | 1/20 | 0.90 |
| ▸ | CDK7 known ✓ | P50613 | 1/20 | 0.90 |
| ▸ | CDK3 known ✓ | Q00526 | 1/20 | 0.90 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 0.90 |
| ▸ | CDK16 known ✓ | Q00536 | 1/20 | 0.90 |
| ▸ | CDK17 known ✓ | Q00537 | 1/20 | 0.90 |
| ▸ | CDK18 known ✓ | Q07002 | 1/20 | 0.90 |
| ▸ | CDK13 known ✓ | Q14004 | 1/20 | 0.90 |
| ▸ | CDK15 known ✓ | Q96Q40 | 1/20 | 0.90 |
| ▸ | CDK19 known ✓ | Q9BWU1 | 1/20 | 0.90 |
| ▸ | CDK12 known ✓ | Q9NYV4 | 1/20 | 0.90 |
| ▸ | CCNY | Q8ND76 | 10/20 | 0.90 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.90 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| At-7519 SCHEMBL21134171 | 0.95 | CDK2 (1.00) | CDK14CCNYCDK2CCNA2CDK1 | |
| At-7519 SCHEMBL29686205 | 0.94 | CDK2 (0.98) | CDK14CCNYCDK2CCNA2CDK1 | |
| At-7519 SCHEMBL30439334 | 0.88 | CDK2 (1.00) | CDK14CCNYCDK2CCNA2CDK1 | |
| SCHEMBL17252164 | 0.86 | CDK14 (0.70) | CDK14CCNYCDK2CCNA2CDK1 | |
| At-7519 SCHEMBL1072294 | 0.80 | CDK5 (0.61) | CDK14CCNYCDK2CCNA2CDK1 | |
| At-7519 SCHEMBL16318377 | 0.80 | CDK5 (0.61) | CDK14CCNYCDK2CCNA2CDK1 | |
| SCHEMBL30915456 | 0.77 | CDK5 (0.57) | CDK14CCNYCDK2CCNA2CDK1 | |
| SCHEMBL22022383 | 0.76 | CDK5 (0.59) | CDK14CCNYCDK2CCNA2CDK1 | |
| At-7519 SCHEMBL955568 | 0.74 | CDK5 (0.67) | CDK14CCNYCDK2CCNA2CDK1 | |
| SCHEMBL2425448 | 0.73 | CDK5 (0.55) | CDK14CCNYCDK2CCNA2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332145-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2025-10-30 | — | — | US | claimed |
| US-12383529-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | claimed |
| EP-4580631-A1 | DOSAGE REGIMENS OF ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| US-20250120968-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2025-04-17 | — | — | US | claimed |
| WO-2025007920-A1 | COMBINED DRUG FOR DEGRADING ESTROGEN RECEPTOR AND USE THEREOF | 海创药业股份有限公司 | 2025-01-09 | — | — | WO | claimed |
| CN-119258223-A | Combined medicine for degrading estrogen receptor and application thereof | 海创药业股份有限公司 | 2025-01-07 | — | — | CN | claimed |
| US-20240390325-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2024-11-28 | — | — | US | claimed |
| US-11925618-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2024-03-12 | — | — | US | claimed |
| WO-2024049926-A1 | DOSAGE REGIMENS OF ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. (US) | 2024-03-07 | — | — | WO | claimed |
| EP-4259137-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2023-10-18 | — | — | EP | claimed |
| CN-116744925-A | Method for treating breast cancer using tetrahydronaphthalene derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2023-09-12 | — | — | CN | claimed |
| EP-4021450-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| CN-114667147-A | Method for treating breast cancer using tetrahydronaphthalene derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| WO-2022132652-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| US-20220193072-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADER | ARVINAS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| US-20220168273-A1 | Pharmaceutical Combination for the Treatment of Cancer | Piramal Enterprises Limited (IN) | 2022-06-02 | — | — | US | claimed |
| US-11234963-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2022-02-01 | — | — | US | claimed |
| EP-4724045-A1 | SOLID ORAL DOSAGE FORMS OF ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-11234963-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2022-02-01 | — | — | US | disclosed |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | CXCR4, CXCR6, TLR7 | CDK14 731/4885CDK2 1170/4885CDK1 1291/4885 |
| US-20250120968-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | CDK14 799/4885CDK2 267/4885CDK1 340/4885 |
| US-20220193072-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADER | ESR1, GPER1, ESR2 | CDK14 839/4885CDK2 285/4885CDK1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.